For example, the "Comparison of Age-related Macular Degeneration Treatments Trials" (CATT) research group observed that among the 1011 participants who were not affected by GA at baseline and were undergoing anti-VEGF therapy, there was a cumulative incidence of GA of 12% at one year, 17% after two years, and 38% at five years [150]. This evidence concerns the gene VEGFA and age-related macular degeneration.